Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current VERV market cap is 449.56M. The company's latest EPS is USD -2.3631 and P/E is -2.25.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.09M | 3.12M | 5.14M | 5.7M | 6.69M |
| Operating Income | -58.58M | -52.33M | -53.95M | -56.84M | -58.84M |
| Net Income | -53.98M | -45.76M | -48.35M | -48.74M | -49.81M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 1.94M | 11.76M |
| Operating Income | -13.64M | -40.63M | -87.07M | -165.69M | -223.12M |
| Net Income | -19.3M | -45.7M | -120.31M | -157.39M | -200.07M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 589.13M | 612.41M | 752.69M | 732.36M | 700.91M |
| Total Liabilities | 123.91M | 152.04M | 153.19M | 149.29M | 154.82M |
| Total Equity | 465.22M | 460.37M | 599.5M | 583.07M | 546.09M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 21.65M | 78.41M | 384.12M | 679.22M | 752.69M |
| Total Liabilities | 15.72M | 17.16M | 26.77M | 128.29M | 153.19M |
| Total Equity | -19.55M | -63.91M | 357.35M | 550.93M | 599.5M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -97.06M | -108.87M | -149.55M | -43.08M | -77.24M |
| Investing | 48.42M | 36.58M | 27.69M | -41.63M | -11.48M |
| Financing | 3.27M | 35.19M | 212.58M | 22.73M | 24.03M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -7.44M | -35.27M | -77.88M | -122.33M | -149.55M |
| Investing | -12.76M | -51.13M | -239.1M | -155.96M | 27.69M |
| Financing | 17.95M | 92.63M | 377.09M | 328.96M | 212.58M |
| Market Cap | 449.56M |
| Price to Earnings Ratio | -2.25 |
| Price to Sales Ratio | 38.23 |
| Price to Cash Ratio | 2.18 |
| Price to Book Ratio | 0.75 |
| Dividend Yield | - |
| Shares Outstanding | 84.66M |
| Average Volume (1 week) | 1.43M |
| Average Volume (1 Month) | 1.66M |
| 52 Week Change | -57.25% |
| 52 Week High | 19.34 |
| 52 Week Low | 4.305 |
| Spread (Intraday) | 0.74 (13.24%) |
| Company Name | Verve Therapeutics Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.vervetx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
